Capricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Recommendation of "Buy" by Brokerages

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) has earned a consensus rating of "Buy" from the five research firms that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $22.60.

A number of equities research analysts have issued reports on the company. Oppenheimer reaffirmed an "outperform" rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Maxim Group lifted their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a "buy" rating in a report on Wednesday, September 25th. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a report on Wednesday. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $8.00 target price on shares of Capricor Therapeutics in a research report on Friday, September 20th.

Insider Activity at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the firm's stock in a transaction on Friday, September 20th. The stock was bought at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the transaction, the insider now owns 7,090,351 shares of the company's stock, valued at $38,004,281.36. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 12.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in Capricor Therapeutics in the third quarter valued at $133,000. Marshall Wace LLP acquired a new stake in shares of Capricor Therapeutics in the second quarter valued at about $426,000. Renaissance Technologies LLC boosted its holdings in Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock worth $656,000 after buying an additional 84,350 shares in the last quarter. Main Street Financial Solutions LLC grew its position in Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock worth $131,000 after buying an additional 7,500 shares during the period. Finally, Rhumbline Advisers purchased a new position in Capricor Therapeutics in the second quarter valued at about $147,000. Institutional investors and hedge funds own 21.68% of the company's stock.

Capricor Therapeutics Price Performance

Shares of NASDAQ CAPR traded up $0.63 during midday trading on Friday, hitting $17.77. The company's stock had a trading volume of 4,593,738 shares, compared to its average volume of 1,081,583. The firm has a market capitalization of $568.27 million, a price-to-earnings ratio of -20.43 and a beta of 4.01. The business's fifty day simple moving average is $7.44 and its two-hundred day simple moving average is $6.07. Capricor Therapeutics has a 1 year low of $2.68 and a 1 year high of $21.98.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The business had revenue of $3.97 million during the quarter, compared to analysts' expectations of $4.51 million. Analysts anticipate that Capricor Therapeutics will post -1.13 EPS for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.